Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 18Recruiting 16Terminated 2Suspended 2Not yet recruiting 1Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Ann Arbor Stage II Mantle Cell Lymphoma 1

Interventions

Specimen Handling 60Magnetic Resonance Spectroscopy 43Carboplatin 33Cyclophosphamide 31Gemcitabine 28Biopsy 26Cisplatin 25pembrolizumab 24Bevacizumab 24Paclitaxel 23Injections 22Standard of Care 21Radiotherapy 21Drug Therapy 21Capecitabine 21fludarabine 20venetoclax 19Oxaliplatin 19toripalimab 17Nivolumab 17Interviews as Topic 17Dexamethasone 17Blood Specimen Collection 16anlotinib 15Radiosurgery 15tislelizumab 14Azacitidine 14cemiplimab 13Pemetrexed 13Irinotecan 12

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × deltacortene × 90 days × Clear all
NCT07444710 2026-05-13

Testing the Addition of an Anti-Cancer Drug, Glofitamab, to the Usual Chemotherapy Treatment (Alternating R-CHOP/R-DHAP) for Previously Untreated Mantle Cell Lymphoma

National Cancer Institute (NCI)

Phase 1 Not yet recruiting
16 enrolled
Lymphoid

Ann Arbor Stage II Mantle Cell Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡